Table 4.

Logistic regression results evaluating the predictors of clinically meaningful ADC value increase and decrease after chemotherapy

Parameters	ADC values increase (n = 91)^a	ADC values decrease (n = 10)^a	p value
Age	1.103 (0.920–1.322)	0.907 (0.756–1.087)	0.289
Gender	1.787 (0.164–19.475)	0.560 (0.051–6.089)	0.634
RISS stage	0.153 (0.008–3.074)	2.536 (1.132–5.684)	< 0.001^b
Type of MM	0.394 (0.176–0.884)	6.542 (0.325–131.52)	0.005^b
β2-MG	2.406 (1.094–5.294)	0.416 (0.189–0.914)	0.002^b
Albumin	0.955 (0.795–1.146)	1.048 (0.872–1.258)	0.619
LDH	1.007 (0.977–1.038)	0.993 (0.964–1.023)	0.646
p53 deletion	1.257 (0.022–71.310)	0.796 (0.014–45.143)	0.912
IGH rearrangement	1.036 (0.978–2.012)	1.074 (1.005–1.995)	0.007^b
q21 amplification	0 (0 to + ∞)	0 (0 to + ∞)	0.997
RB1 deletion	8.963 (0.167–48.145)	0.112 (0.002–5.980)	0.280
p32 deletion	62.549 (0.120–32.659)	0.560 (0.051–6.098)	0.634

ADC apparent diffusion coefficient, LDH lactic dehydrogenase, MM multiple myeloma, RISS revised international staging system

^aThe values are given as the odds ratio, with 95% confidence interval in parentheses

^bSignificant difference